COMMUNIQUÉS West-GlobeNewswire

SS Innovations Reports First Quarter 2026 Financial Results
13/05/2026
Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations [...]
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
13/05/2026
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
13/05/2026
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first [...]
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
13/05/2026
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
13/05/2026
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 Program targets [...]
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
13/05/2026
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]
IBA lance AdaPTinsight XR, la nouvelle génération d’imagerie CBCT pour la protonthérapie guidée par l’image
13/05/2026
Une solution d’imagerie CBCT pour les systèmes de protonthérapie Proteus ® offrant une visibilité claire qui permet des traitements IGPT en toute confiance Louvain-la-Neuve, Belgique, le 13 mai 2026 – IBA (Ion Beam [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1, [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]
IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy
13/05/2026
Proton therapy CBCT imaging solution across Proteus ® Portfolio providing clarity and confidence in IGPT Louvain-la-Neuve, Belgium, May 13, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
Fortis Life Sciences attribue la subvention à la découverte AbNano® VHH Discovery 2026 à Deliver Biosciences pour la recherche sur l’administration ciblée de médicaments
13/05/2026
Le programme de subvention élargit l’accès aux technologies d’anticorps à domaine unique avancées, afin de soutenir la recherche et le développement des traitements de nouvelle génération BOSTON et LONDRES, 13 mai 2026 [...]
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Inventiva to Present Abstracts at the EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
13/05/2026
Almost a third of adults taking Wegovy ® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 [...]
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
13/05/2026
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 1 Program launched in April to further reduce [...]
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 – Inventiva (Euronext Paris et NASDAQ: IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le [...]

Pages